ERA PerMed is an ERA-Net Cofund, supported by 32 partners of 23 countries and co-funded by the European Commission. To align national research strategies, promote excellence, reinforce the competitiveness of European players in Personalised Medicine (PM), and enhance the European collaboration with non-EU countries, 32 funding organisations have agreed to launch the fifth joint transnational call for collaborative innovative research projects in Personalised Medicine (PM). This represents the fourth call not co-funded by the European Commission. The funding organisations participating in this call particularly wish to promote innovative interdisciplinary collaboration and to encourage translational research proposals. The available budget for this call is 27 Mio€ (approx.).
Expected date for call to be launched: 1st December 2021
Submission expected deadline for pre-proposals: 17 February 2022
Submission expected deadline for invited full-proposals: 14 June 2022
The International Consortium for Personalised Medicine (ICPerMed) has elaborated the following videos to explain the activities of ICPerMed and the ICPerMed family, that includes the ERA-Net ERA PerMed, which serves to foster the development of personalised medicine through research project funding.
For all videos, five subtitles are available: English, French, German, Italian and Spanish.
About the International Consortium for Personalised Medicine -ICPerMed introduction video
ICPerMed provides a platform to initiate and support communication and exchange on personalised medicine research, funding and implementation. The high-level participation from all over Europe and beyond enables ICPerMed to efficiently map the scientific and political landscape, allowing an alignment of research and funding activities on European and international level and fostering actions toward personalised medicine implementation. ICPerMed was initially developed as European initiative but is acting globally to foster the development of “Next Generation Medicine”.
ERA PerMed_ Fostering the development of personalised medicine through RESEARCH PROJECT FUNDING
The European Research Area Network (ERA-Net Cofund) for Personalised Medicine, ERA PerMed, aligns research and funding activities and transforms ICPerMed’s strategic reflections into reality. In 2023, after launching in total 5 annual calls, over 100M€ will be invested in personalised medicine research through ERA PerMed in cancer, neurosciences, infectious diseases and other medical fields.
The importance of REGIONS for personalised medicine development and implementation
Healthcare is often organised at the regional level. We can capitalise on a region’s knowledge, research, development, investment, and innovative implementation pilots, to further scale-up personalised medicine approaches. Learn more about the CSAs SAPHIRe and Regions4PerMed.
INTERNATIONAL COLLABORATION: “Healthy lives for all at all ages”
The common understanding of personalised medicine, the promotion of international standards and global collaborations, are key to fostering the uptake of personalised approaches in healthcare. International collaboration is essential to ensure that personalised medicine approaches are applicable as broadly as possible and not limited to a specific regional context, to make healthcare more efficient and equitable. EULAC-PerMed, Sino-EU PerMed, IC2PerMed and EU-Africa PerMed foster the exchange with Latin American and Caribbean countries, China and African countries, respectively and build bridges between the EU and these regions.
HEALTH ECONOMICS and CLINICAL PERSPECTIVE
The implementation of personalised medicine approaches requires suitable frameworks around infrastructures, funding and regulatory procedures: From patient stratification, clinical development and uptake in practice, to reimbursement. PERMIT is focusing its reflections on clinical trial design in personalised medicine. HEcoPerMed aims to identify the best health economic modelling and payment strategies for personalised medicine.
They encourage any academic researcher regardless of their research focus and current level (or absence) of engagement with patients to help them learn more about patient engagement and to further define resources and tools that can shape future patient engagement in research and development.
The Agreement on Scientific-Technological Cooperation between Canada and Germany entered into force on 30 June 1971. The 16th Special Edition of the ITB infoservice is thus dedicated to the 50th anniversary of the scientific-technological cooperation between Canada and Germany.
The Annual Leipzig interactive Nephro-Seminar (LiNS) will take place in Leizpig, on 11th-12th September 2021. This seminar is organised in association with the ERA PerMed funded projects PersTIGan, Kidney Attack, ProDial and the Covid project Crit-Cov.
The multidisciplinary 2-day program will adress a multitude of nowadays clinical and related basic research issues, by combination of globally renowned clinical and basic lecturers. The meeting will bi-lingual, with the practical nephrological issues on Sept. 11th in German and the omics discussion mostly in English.
The program and all the information of the Seminar is available on: